Skip to main content Skip to search Skip to main navigation

ICMRA: Regulatory Collaboration Pilots

The International Coalition of Medicines Regulatory Authorities (ICMRA) is announcing the initiation of two regulatory collaboration pilots addressing facility inspections and Chemistry and Manufacturing Controls (CMC) and Post-Approval Change (PAC) submission assessments and related regulatory actions.

The pilots are being operationalized under the auspices of ICMRA to explore the feasibility and potential for further collaboration and convergence among regulators in specific data expectations and assessment approaches when assessing manufacturing facilities for Pre-Approval and Pre-License Applications (PAIs & PLIs) and reviewing PACs and PAC Management Protocols. 

The two pilots, one focused on collaborative assessments of CMC submissions, and the other on hybrid inspections, are to inform pre-market or PAC CMC assessment of drug applicants.  Each of the pilots will involve two or more National Regulatory Authorities collaborating in the effort.  Please note that the actual post approval change submission should follow the normal regulations and procedures in each participating region.

Each pilot aims to conduct three assessments or collaborative hybrid inspections over an anticipated duration of 1-1.5 years, and then issue learnings and recommendations on how to operationalize these programs in the future to benefit Industry and Regulators.


Source:

ICMRA: Pharmaceutical Quality – Regulatory Collaboration Pilots: Call for Industry Applications

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What is a gas?

What is a gas?

You can view the answer here:
Read more
EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

The European Pharmacopoeia (Ph. Eur.) has introduced a new general chapter that provides a framework for managing the quality of data, including digital data, throughout its life cycle.

Read more
EMA: Pilot Programme for Breakthrough Devices

EMA: Pilot Programme for Breakthrough Devices

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
Previous
Next